- Home
- OPAL vs GALT Comparison
OPAL vs GALT Comparison
Compare OPAL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAL
- GALT
- Stock Information
- Founded
- OPAL 1998
- GALT 2000
- Country
- OPAL United States
- GALT United States
- Employees
- OPAL N/A
- GALT N/A
- Industry
- OPAL Natural Gas Distribution
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- OPAL Utilities
- GALT Health Care
- Exchange
- OPAL Nasdaq
- GALT Nasdaq
- Market Cap
- OPAL 73.6M
- GALT 83.5M
- IPO Year
- OPAL N/A
- GALT N/A
- Fundamental
- Price
- OPAL $2.44
- GALT $3.75
- Analyst Decision
- OPAL Sell
- GALT Buy
- Analyst Count
- OPAL 4
- GALT 2
- Target Price
- OPAL $2.81
- GALT $6.00
- AVG Volume (30 Days)
- OPAL 152.4K
- GALT 319.1K
- Earning Date
- OPAL 08-06-2025
- GALT 08-12-2025
- Dividend Yield
- OPAL N/A
- GALT N/A
- EPS Growth
- OPAL N/A
- GALT N/A
- EPS
- OPAL 0.02
- GALT N/A
- Revenue
- OPAL $320,427,000.00
- GALT N/A
- Revenue This Year
- OPAL $22.45
- GALT N/A
- Revenue Next Year
- OPAL $19.70
- GALT N/A
- P/E Ratio
- OPAL $126.20
- GALT N/A
- Revenue Growth
- OPAL 15.22
- GALT N/A
- 52 Week Low
- OPAL $1.26
- GALT $0.73
- 52 Week High
- OPAL $4.21
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- OPAL 45.96
- GALT 73.15
- Support Level
- OPAL $2.43
- GALT $2.54
- Resistance Level
- OPAL $2.63
- GALT $3.15
- Average True Range (ATR)
- OPAL 0.10
- GALT 0.26
- MACD
- OPAL 0.01
- GALT 0.02
- Stochastic Oscillator
- OPAL 48.00
- GALT 95.73
About OPAL OPAL Fuels Inc.
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.